Androtag (Testosterone)

Quick links to important sections

Androtag (Testosterone)

Treatment option: Hypogonadism

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Androtag (Testosterone)

Property Description
Active ingredient Testosterone (INN)
Form Transdermal Gel or Solution
Pharmacological class Androgen, Anabolic Steroid
Common use Testosterone Replacement Therapy (TRT)
Origin Naturally occurring hormone, synthetically prepared

What Type of Medicine is Androtag (Testosterone)?

Androtag (Testosterone) is a prescription-only pharmaceutical classified as an androgen, used for hormone replacement therapy to address low testosterone levels in adult males. The active ingredient, Testosterone (INN), belongs to the class of anabolic steroids and androgenic hormones. The preparation contains the synthetic version of the naturally occurring male hormone and is categorized as a Controlled Substance in the U.S., distinguishing it from many non-controlled topical medications.

Form and Composition of Androtag

Androtag is commonly supplied as a transdermal gel or solution intended for topical application onto the skin. This delivery method, which avoids tablets or injections, is a key differentiating feature of the product form. The active Testosterone is integrated into a hydroalcoholic gel base, which serves as the vehicle to facilitate its absorption through the skin. Transdermal forms are designed to achieve stable levels of bioavailable testosterone in the blood, offering a unique profile compared to other delivery systems.

General Purpose of Testosterone Replacement Therapy (TRT)

The primary purpose of Androtag is to serve as Testosterone Replacement Therapy (TRT) for men diagnosed with clinical hypogonadism. This condition indicates that the body produces insufficient levels of the androgen hormone. By restoring hormonal balance, the medication is intended for supporting and maintaining various vital functions. Testosterone is necessary for the maintenance of male secondary sex characteristics and overall well-being in deficient males. This hormone serves an essential function in regulating key physiological processes.

Regulatory References

  1. National Institutes of Health
  2. World Health Organization (WHO) Testosterone Entry
  3. WHO Model List of Essential Medicines (EML) official site

What side effects are possible with Androtag (Testosterone)?

Possible Side Effects and Safety Information

The safety profile of Testosterone therapy is officially documented across regulatory sources, classifying adverse reactions by frequency and the body system affected. These classifications are based on data reviewed by health authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Frequency and System-Organ Classification

Adverse reactions classified as Common (affecting up to 1 in 10 patients) often include effects on the skin and blood. Frequently documented reactions are acne, localized application site reactions (such as irritation or redness) specific to the transdermal form, headache, hypertension, and an increase in Prostatic Specific Antigen (PSA). Additionally, an increase in hematocrit and hemoglobin (polycythemia) is commonly noted, which affects the Blood and Lymphatic System.

Documented Serious Adverse Reactions

Official regulatory texts highlight specific serious risks associated with testosterone use. These include the potential for Venous Thromboembolism (VTE), specifically Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). The medication is also known to stimulate androgen-sensitive tissue and is contraindicated in men with known or suspected Prostate Cancer or Breast Cancer. The therapy may also exacerbate pre-existing sleep apnea in susceptible individuals.

Population-Specific Safety Considerations

Regulatory documents specify heightened caution for certain groups. Older adults require increased monitoring for prostate-related events. Patients with severe cardiac, hepatic, or renal insufficiency are at an increased risk of edema (fluid retention), which may worsen pre-existing congestive heart failure. Effects like elevated PSA and polycythemia are associated with long-term exposure and necessitate routine monitoring.

Overdose and Emergency Response

Overdose and When to Seek Help

The officially documented profile for overdose of transdermal testosterone, such as Androtag, focuses on signs of excessive androgen exposure, which are generally an exaggeration of known adverse effects [1.3]. Overexposure may result from inappropriate application or, in severe cases, abuse [1.2].

Documented Manifestations Regulator-Mandated Action
Clinical Signs: Irritability, nervousness, weight gain, nausea, Priapism (too frequent or persistent erections), and ankle swelling (oedema) [1.3]. If signs of excessive androgen exposure occur, the product should be discontinued or the dosage must be reviewed [1.3].
Serious Outcomes: Venous Thromboembolism (VTE), including Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) [1.4]; Myocardial Infarction or Stroke [2.1]. Seek medical attention immediately for symptoms of heart attack (e.g., chest pain, trouble breathing) or stroke (e.g., sudden weakness, slurred speech) [2.1].
Laboratory/Physiological: Elevated Hematocrit and Hemoglobin (Polycythemia), which may increase the risk of thromboembolic events [1.4]. If hematocrit becomes elevated, therapy must be stopped until the level returns to an acceptable concentration [1.4].
Special Risk: Severe Oedema with or without Congestive Cardiac Failure (CHF) in patients with pre-existing cardiac, hepatic, or renal disease [1.3]. Treatment must be stopped immediately if severe complications such as CHF occur [1.3].

Overdose Management:

No specific antidote is known for testosterone overexposure [2.1]. Management involves discontinuation of the product and the use of symptomatic and supportive treatment to address manifested signs and symptoms [2.1]. For secondary exposure in unintended populations, the product must be promptly discontinued until the cause of virilization is identified [1.1].

Therapeutic Uses of Androtag (Testosterone)

What Androtag (Testosterone) Treats: Main Uses and Benefits

Androtag (Testosterone) is used as a Testosterone Replacement Therapy (TRT) for adult men diagnosed with Clinical Hypogonadism—a chronic condition where the body does not produce sufficient androgen hormone. The medication is considered relevant for managing the resulting symptomatic deficiency, providing support across domains where symptoms interfere with daily functioning.

The medication is commonly used to help with the symptoms of this deficiency by replacing the natural hormone. The treatment is intended to help with symptom clusters that may become disruptive, such as those related to sexual desire and physical stamina, as well as mood changes associated with the deficiency.

Supporting Symptomatic Relief

Quick Fact: Relief for Chronic Fatigue

The medication supports patients during difficult episodes by easing the symptom load, which may assist with maintaining functional stability. The therapy is applied when symptoms are driven by systemic imbalance, helping to address distressing symptoms such as reduced libido, persistent fatigue, and difficulties with concentration. The use is relevant when supportive symptom management is appropriate across physical, psychological, and sexual symptom domains, contributing to improved comfort during periods of heightened distress and supporting general well-being.

Regulatory References

  1. NIH MedlinePlus overview on Testosterone

Eligibility and Restrictions for Use

Androtag (Testosterone) is officially authorized for use only in adult males (18 years of age and older) to treat conditions related to the absence or deficiency of the endogenous hormone. Eligibility is strictly defined by regulatory documents and includes several absolute prohibitions.

The medicine is contraindicated and must not be used by women, including those who are pregnant or breastfeeding. Furthermore, use is absolutely prohibited in men with known or suspected carcinoma of the breast or prostate carcinoma due to the potential for androgen-dependent tumor progression. Contraindication also applies to patients with known hypersensitivity to the active substance or excipients.

Use is not recommended or not established for pediatric males (under 18 years), as safety and efficacy have not been sufficiently documented, and there is a risk of accelerating bone age. Use requires caution and close monitoring in patients with pre-existing conditions such as severe cardiac, hepatic, or renal impairment, severe sleep apnea, or uncontrolled hypertension. Closer monitoring may also be necessary for older adults due to insufficient long-term safety data regarding prostate and cardiovascular risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific pharmacodynamic and metabolic interactions for co-administered medicinal products with Androtag (Testosterone).


Documented Interaction Patterns

The interaction profile is primarily structured around the effects of androgens on other systems, necessitating precautionary measures.

  • Oral Anticoagulants: Co-administration with oral anticoagulants, such as Warfarin, may lead to a change in the anticoagulant activity, which is typically an increase in effect. Regulatory labels require frequent monitoring of the International Normalized Ratio (INR) and prothrombin time when testosterone therapy is initiated, adjusted, or discontinued.

  • Anti-diabetic Agents: Testosterone may decrease blood glucose levels. This metabolic effect means that patients taking Insulin or other Anti-diabetic Agents may require an adjustment in the dose of their anti-diabetic medication to prevent hypoglycemia.

  • Corticosteroids and ACTH: Concurrent use with Corticosteroids or Adrenocorticotropic Hormone (ACTH) carries a documented risk of an additive pharmacodynamic effect, resulting in increased fluid retention (edema).


Population-Specific Constraints

The documented interaction leading to fluid retention is a particular caution in specific patient populations. Due to the potential for exacerbating conditions, the co-administration with Corticosteroids/ACTH requires careful monitoring, particularly in patients with underlying cardiac disease, renal disease, or hepatic disease. No medicinal product combinations are formally classified as contraindicated due to an interaction mechanism, and there are no mandatory timing-based separation rules for co-administered medicines.

Mechanism of Action

️ Genomic Signaling and Receptor Agonism

Androtag (Testosterone) acts by activating the intracellular Androgen Receptor (AR), initiating a genomic cascade that leads to widespread physiological change. The drug is an AR agonist, with the hormone-receptor complex translocating to the cell nucleus and binding directly to DNA to modulate the transcription of specific genes. This mechanism focuses on the long-term regulation of cellular processes rather than rapid signaling.


Metabolic Activation and Co-Signaling

The full scope of the mechanism requires enzymatic conversion of Testosterone to two active molecules: Dihydrotestosterone (DHT) and Estradiol (E2). DHT enhances androgenic signaling in local tissues, while E2 activates Estrogen Receptors (ER). This co-signaling via both AR and ER is essential for certain bone and CNS functions, contributing to the full spectrum of physiological response.


Modulation of Protein Turnover and Hematopoiesis

The resulting changes in gene expression drive anabolic pathways, increasing the rate of protein synthesis and decreasing protein breakdown in muscle and bone cells. This directly leads to modulation of protein accretion and changes in bone mineral composition, and also stimulates erythropoiesis (red blood cell production) via modulation of EPO. The mechanism modulates the balance of protein synthesis relative to protein degradation.

Dosage and Administration Information

How to Use Androtag (Testosterone)

Testosterone replacement therapy using transdermal products follows specific protocols concerning administration route, dosage, timing, and procedural steps. This medication is intended for topical use only, with application restricted to designated skin areas, such as the shoulders and upper arms, to facilitate absorption.


Dosing and Frequency

Administration follows a once-daily pattern, with application occurring at approximately the same time each morning to help mimic the natural physiological rhythm of testosterone production. Dosing begins with a specified starting daily dose (e.g., 40.5 mg or 50 mg of testosterone, depending on the product concentration). The required maintenance dose is determined through a titration protocol.

Serum testosterone concentration is typically measured by a healthcare provider around 14 to 28 days after treatment initiation or a dose change to guide this adjustment process. The final maintenance dose aims to keep hormone levels within the mid-normal range.


Application Procedures and Constraints

Before initial use, metered-dose pumps must be primed by depressing the pump a specified number of times, discarding the initial material to ensure dose accuracy. Immediate post-application hygiene is essential: hands must be washed thoroughly with soap and water after application. The application site must be covered with clothing once dry to mitigate the risk of accidental transfer to other individuals. Furthermore, contact with water, such as showering or swimming, should be avoided for a defined period, generally two to five hours, following application to ensure proper absorption. Use of this medication is not established in males under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Androtag (Testosterone)

Evidence for Symptomatic Male Hypogonadism

Research exploring this medicine focuses primarily on adult men diagnosed with Symptomatic Male Hypogonadism, a condition marked by low testosterone levels and associated physical or psychological complaints. The evidence base includes multiple placebo-controlled randomized controlled trials (RCTs) and systematic reviews that evaluated changes over short and intermediate periods. These studies were applied in research exploring how symptoms change over time and examining patient-reported experiences. The findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

The trials evaluated outcomes related to functional imbalance, such as sexual desire and erectile function, using specific medical questionnaires. The evidence contributes to understanding symptom patterns, and findings related to these sexual outcomes were reported in many studies. Research also examined changes in body composition, specifically evaluating shifts in lean body mass and fat mass. Studies report how symptoms evolved in the observed populations, with findings describing patterns related to changes in lean body mass in the observed populations.

Outcomes related to physical discomfort, such as fatigue and general quality of life (QoL), were studied for how symptoms are measured in observational settings evaluating daily-life functioning. However, findings across these specific symptomatic endpoints have been mixed or inconsistent, suggesting certainty remains low for a clear pattern in these areas. Short-term research focused on episodes where symptoms become more noticeable, but long-term effects are not fully established for these patient-reported outcomes.


Outcomes Measured in Clinical Trials

Beyond symptoms, research explored other outcomes reflecting daily functioning or activity level. Studies examined bone mineral density (BMD), a measure of bone strength, in populations with longer follow-up periods. Findings related to BMD were observed in some studies, but the patterns were not consistently described across all research, and evidence quality varies across studies.

Research also examined temporary physiological imbalance by evaluating metabolic markers. This includes measuring levels of blood sugar (such as HbA1c) and various lipid profiles (cholesterol and triglycerides) in the study populations. Findings indicate patterns where shifts in these metabolic measurements were reported in some individuals, particularly in cohorts with co-existing conditions. These studies help show what has been observed so far, but comparative evidence is lacking, and follow-up durations were limited in these specific areas.


Evidence in Specific Subgroups and Comorbidities

Research explored adult men with conditions characterized by functional limitations, such as those with co-existing Type 2 Diabetes Mellitus and Metabolic Syndrome. In these populations, treatment was studied for its effect on blood sugar control and lipid levels.

Research has also explored the application of the medicine in specific age groups for research purposes. Trials and post-marketing studies included data for older men, typically those aged 65 and above, including men with established or high Cardiovascular (CV) risk factors. These studies tracked responses over defined time intervals to compare how outcomes and reported experiences were captured relative to the younger, general hypogonadal population. It is noted that results apply only to the populations studied, and data for certain groups, such as very elderly individuals, remain insufficient.


Long-Term Follow-up and Durability of Response

While many placebo-controlled trials assess changes over short periods (often 12 to 30 weeks), research explored short-term symptom changes, and research indicates that the patterns of change observed initially may require extended follow-up to understand durability.

The assessment of long-term outcomes and the durability of changes reported in short-term trials often relies on long-term observational studies and patient registries. These settings evaluating daily-life functioning have been used to monitor large groups of patients for periods extending up to five years, and in some cases, over a decade. This research provides context but not individual predictions, describing patterns related to physical and hormonal status over time. However, long-term effects are not fully established, as these studies are not randomized and face different research limitation frames, such as confounding factors that are challenging to control.


Evidence Gaps and Areas of Uncertainty

The body of evidence is comprehensive in some areas, but certain aspects remain insufficiently studied. Evidence for long-term outcomes is not well characterized, as few large-scale RCTs have followed participants beyond two to three years. There is limited information for long-term outcomes related to patient-reported outcomes like mood, energy, and cognitive function, where findings were mixed across the short-term trials.

The sample sizes were modest in many early studies, and evidence quality varies across studies, particularly for the investigation of long-term outcomes or less common events. Research activities continue in multiple areas to help contextualize how patients reported their experience. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Androgens (Testosterone) - MedlinePlus Drug Information (Pharmacological Class)
  2. Testosterone Topical - MedlinePlus Drug Information (Use and Symptoms)

Frequently Asked Questions (FAQ)

Common questions about Androtag (Testosterone) (FAQ)


Q: Does Androtag actually help with energy levels?

Testosterone treatment has been studied for its potential effects on symptoms like fatigue. However, official information indicates that clinical studies have shown mixed or inconsistent results regarding clear patterns of change in general energy levels and quality of life.


Q: Can taking Androtag affect my heart health?

Regulatory documents state that testosterone therapy can be associated with an increase in blood pressure and is not recommended for men with uncontrolled high blood pressure. The medication is associated with a risk of developing venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). In patients with pre-existing heart disease, fluid retention (edema) can occur, which may be serious and is a condition for which regulatory documents specify close monitoring.


Q: How often do people generally need to see a doctor when starting Androtag?

Routine monitoring of hormone levels is specified in official guidelines. Serum testosterone levels are typically measured approximately two to four weeks after starting treatment or after any dose change to guide adjustments. Patients also require regular checks of blood parameters, such as hematocrit, and prostate health indicators, such as PSA, periodically throughout the therapy.


Q: What's the difference between Androtag and other types of testosterone products?

The primary difference lies in the method of administration. Androtag is a transdermal gel or solution intended for topical application onto the skin. Official sources confirm that other government-approved testosterone products are available as injections, patches, or oral systems. The specific formulation is a key differentiating feature.


Q: Does Androtag change mood or behavior?

Official product information notes that adverse reactions affecting the central nervous system have been reported during testosterone therapy. These include instances of mood swings, emotional instability, irritability, and nervousness. Additionally, aggressive behavior has been reported in cases involving the misuse or abuse of testosterone at high doses.


Q: Is Androtag considered a long-term treatment?

Testosterone replacement therapy is used to manage chronic low hormone conditions. Due to the chronic nature of the therapy, official guidelines recommend routine monitoring for risks associated with long-term exposure, such as polycythemia (high red blood cell count) and elevated PSA. However, studies on the long-term safety profile, especially for geriatric patients, are still under examination.


Q: What is polycythemia, and why is it sometimes mentioned with Androtag?

Polycythemia is a medical term for an increase in the number of red blood cells in the blood. Regulatory sources list an increase in hematocrit and hemoglobin as a commonly reported adverse reaction. This occurs because testosterone stimulates erythropoiesis, which is the process of making new red blood cells.


Q: Are there specific symptoms that should prompt me to contact my doctor while on Androtag?

Official patient information highlights certain serious risks for which regulatory documents advise seeking prompt medical attention. These include signs of a blood clot, such as sudden chest pain or difficulty breathing, or pain, swelling, and warmth in the leg. Patients should also observe for symptoms of fluid retention like excessive swelling of the hands or feet, or signs of worsening sleep apnea, which may include new or increased difficulty breathing during sleep.


Q: Is it true that Androtag has different formulas (gel, injection, patch)?

Androtag is specifically labeled and approved as a transdermal gel or solution. While other forms of testosterone are approved by regulatory bodies, Androtag itself is not labeled for use as an injection or patch.


Q: What does the patient information leaflet say about lifestyle factors while on Androtag?

The product information specifies that the product is flammable until dry, so fire, flames, or smoking must be avoided near the application site. The labeling specifies avoiding contact with water, such as showering or swimming, for a specific period after application to support proper absorption.


Q: Can Androtag affect my sleep patterns?

Official labeling states that testosterone therapy may cause or worsen pre-existing sleep apnea in susceptible individuals. Insomnia, or difficulty sleeping, has also been reported as an adverse reaction in post-marketing experience.


Q: How long does it usually take to notice any changes from Androtag?

The time it takes to see changes can vary depending on the effect. Based on study findings, changes in sexual interest may begin to appear within a few weeks of starting treatment. However, full effects on body composition and bone density generally take many months or even over a year to fully manifest.


Q: Why do official documents say Androtag is a controlled substance?

Official product labeling classifies testosterone as a Schedule III controlled substance under the Controlled Substances Act because it has a potential for abuse. Abuse is defined as misuse at higher-than-recommended doses, often in combination with other anabolic agents, which carries serious safety risks.


Q: Is it true that Androtag might cause hair loss?

Hair loss, or alopecia, is listed among the adverse reactions reported in the post-marketing experience for testosterone products.


Q: What is the risk of my body stopping its own testosterone production while using Androtag?

When the body receives external testosterone, official documents note that this suppresses the signals from the pituitary gland that control natural testosterone production. This may result in reduced production by the testicles and, in some cases, may potentially lead to a complete absence of sperm production (azoospermia).


Q: What should I do if I forget to use my Androtag on time?

Regulatory guidance suggests that a missed dose may be applied as soon as it is remembered. However, if it is almost time for the next scheduled dose, the manufacturer’s guidance specifies skipping the missed dose and resuming the regular daily schedule.


Q: Is it possible to develop a dependency on Androtag?

Testosterone products have a documented potential for abuse and dependence, according to official warnings. The labeling notes that patients may experience withdrawal symptoms upon abruptly stopping the medication after misuse or abuse. Symptoms may include fatigue, depression, irritability, and loss of appetite.


Q: What does 'contraindication' mean in the context of Androtag?

A contraindication is a specific reason, based on safety or potential harm, to avoid using a medical treatment. For Androtag, contraindications include being a woman, or a man with known or suspected prostate or breast cancer, due to the potential for the hormone to worsen these conditions.


Q: Why do some people say Androtag is used for 'anti-aging'?

Official regulatory agencies have only approved Androtag for men who have low testosterone due to specific medical conditions (hypogonadism). It is not approved for the treatment of low testosterone related solely to aging.


Q: What is the expected duration of action after using Androtag?

The medication is designed to sustain steady hormone levels over a 24-hour period to support once-daily application. However, the time it takes to see the full physiological benefits on bone and muscle structure can take many months to achieve.


Q: Can using Androtag affect fertility or sperm count?

Official labeling warns that the administration of external testosterone may lead to a decrease in sperm count, which could make it harder to conceive children. This is more common with higher doses, and the effect has the potential to be long-lasting or permanent.


Q: What is the significance of the testosterone 'trough level' test?

The trough level is the measurement of the lowest concentration of testosterone in the blood, typically taken just before the next scheduled dose. This level is tested to ensure that the medication is maintaining the hormone concentration within the target range throughout the entire 24-hour period between applications.


Q: If I stop using Androtag, what generally happens to my testosterone levels?

When the use of external testosterone is discontinued, the body's natural production, which was suppressed during therapy, often begins to resume. However, it may take several months for the natural production and sperm count to return to full recovery.


Q: Is it normal to feel a change in appetite after starting Androtag?

A change in appetite is not listed as a common or frequent adverse reaction during routine use. Official labeling notes that a loss of appetite has been reported as a potential withdrawal symptom upon abrupt discontinuation after drug misuse or abuse.


Q: Why is Androtag used for specific conditions but not others involving hormone imbalance?

Androtag is specifically indicated only for replacement therapy in adult males diagnosed with conditions causing a deficiency of endogenous testosterone, such as primary or secondary hypogonadism. It is not approved or intended for use in other types of hormonal imbalances.


Q: What is the difference between primary and secondary hypogonadism regarding Androtag use?

Official labeling indicates that Androtag is used to treat both types of hypogonadism. Primary hypogonadism is caused by a problem with the testicles, while secondary hypogonadism is caused by an issue with the brain's control centers (the hypothalamus or pituitary gland) that signal the testicles to produce testosterone.

How should Androtag (Testosterone) be stored and disposed of?

How to Store and Dispose of Androtag (Testosterone) Gel

Official regulatory documents define strict rules for storing and discarding Testosterone gel, focusing on maintaining stability and preventing accidental exposure.

Storage Conditions

Requirement Official Regulatory Mandate
Temperature Store at Controlled Room Temperature (25 C / 77 F); keep from freezing and excess heat.
Protection Keep the container tightly closed and away from direct light and excess moisture.
Child Safety Must be kept out of the reach of children and stored in a safe place.
Handling Note The product is flammable until dry; avoid fire, flames, or smoking until the application site has dried.

Disposal Instructions

Used gel packets may be discarded in household trash, provided the disposal method prevents access by children and pets. Any unused or expired medicine must be disposed of in accordance with local requirements for pharmaceutical waste, which typically involves returning it to a pharmacy or using an official drug take-back program. The empty container must also be secured from children and pets upon disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Androtag (Testosterone) found in:

A-Z Index: